Evidence map›Paper›PMID 34575825›Full record

ReviewInternational journal of molecular sciences2021

Identification and Engineering of Aptamers for Theranostic Application in Human Health and Disorders.

Debleena Basu, Sourabrata Chakraborty, Riddhi Pal, Tarun Kumar Sharma, Siddik Sarkar

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Aptamers: Functional-Structural Studies and Biomedical Applications.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Debleena BasuCancer Biology and Inflammatory Disorder, Council of Scientific & Industrial Research-Indian Institute of Chemical Biology, Translational Research Unit of Excellence (IICB-TRUE), Kolkata 700091, India.
Sourabrata ChakrabortyCancer Biology and Inflammatory Disorder, Council of Scientific & Industrial Research-Indian Institute of Chemical Biology, Translational Research Unit of Excellence (IICB-TRUE), Kolkata 700091, India.
Riddhi PalCancer Biology and Inflammatory Disorder, Council of Scientific & Industrial Research-Indian Institute of Chemical Biology, Translational Research Unit of Excellence (IICB-TRUE), Kolkata 700091, India.
Tarun Kumar SharmaAptamer Technology and Diagnostics Laboratory, Multidisciplinary Clinical and Translational Research Group, Translational Health Science and Technology Institute, Faridabad-Gurugram Expressway, Gurugram 121001, India.ORCID 0000-0002-0065-6099
Siddik SarkarCancer Biology and Inflammatory Disorder, Council of Scientific & Industrial Research-Indian Institute of Chemical Biology, Translational Research Unit of Excellence (IICB-TRUE), Kolkata 700091, India.
Indian Institute of Chemical Biology · INTranslational Health Science and Technology Institute · IN

Funding

Science and Engineering Research Board . SRG/2019/001880
6 · The paper itself

Abstract

An aptamer is a short sequence of synthetic oligonucleotides which bind to their cognate target, specifically while maintaining similar or higher sensitivity compared to an antibody. The in-vitro selection of an aptamer, applying a conjoining approach of chemistry and molecular biology, is referred as Systematic Evolution of Ligands by Exponential enrichment (SELEX). These initial products of SELEX are further modified chemically in an attempt to make them stable in biofluid, avoiding nuclease digestion and renal clearance. While the modification is incorporated, enough care should be taken to maintain its sensitivity and specificity. These modifications and several improvisations have widened the window frame of aptamer applications that are currently not only restricted to in-vitro systems, but have also been used in molecular imaging for disease pathology and treatment. In the food industry, it has been used as sensor for detection of different diseases and fungal infections. In this review, we have discussed a brief history of its journey, along with applications where its role as a therapeutic plus diagnostic (theranostic) tool has been demonstrated. We have also highlighted the potential aptamer-mediated strategies for molecular targeting of COVID-19. Finally, the review focused on its future prospective in immunotherapy, as well as in identification of novel biomarkers in stem cells and also in single cell proteomics (scProteomics) to study intra or inter-tumor heterogeneity at the protein level. Small size, chemical synthesis, low batch variation, cost effectiveness, long shelf life and low immunogenicity provide advantages to the aptamer over the antibody. These physical and chemical properties of aptamers render them as a strong biomedical tool for theranostic purposes over the existing ones. The significance of aptamers in human health was the key finding of this review.

Indexed as

Aptamers, NucleotideCOVID-19COVID-19 Drug TreatmentHumansPrecision MedicineSELEX Aptamer TechniqueAptamers, NucleotideaptameraptasensorCOVID-19lateral flow assay (LFA)single cell proteomicssystematic evolution of ligands by exponential enrichment (SELEX)theranostic

Identifiers

PMID34575825
PMCPMC8469434
OpenAlexW3197228307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.